Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Treatment of patients with dual hepatitis C and B by peginterferon ╬▒ and ribavirin reduced risk of hepatocellular carcinoma and mortality.

Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS.

Gut. 2014 Mar;63(3):506-14. doi: 10.1136/gutjnl-2012-304370. Epub 2013 May 15.

PMID:
23676440
2.

Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.

Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.

Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.

PMID:
22024511
3.

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.

Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ; Taiwan Liver-Net Consortium.

Hepatology. 2013 Jun;57(6):2135-42. doi: 10.1002/hep.26266. Epub 2013 Apr 26.

PMID:
23322699
4.

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study.

Yeh ML, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Liang PC, Lin YH, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML.

Medicine (Baltimore). 2015 Oct;94(42):e1837. doi: 10.1097/MD.0000000000001837.

5.

High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.

Chen TM, Lin CC, Huang PT, Wen CF.

Tumour Biol. 2016 Jun;37(6):7129-37. doi: 10.1007/s13277-015-4593-6. Epub 2015 Dec 12.

PMID:
26662957
6.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
7.

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.

Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P.

J Hepatol. 2010 May;52(5):652-7. doi: 10.1016/j.jhep.2009.12.028. Epub 2010 Mar 4.

PMID:
20346533
8.

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.

Kim YJ, Lee JW, Kim YS, Jeong SH, Kim YS, Yim HJ, Kim BH, Lee CK, Park CK, Park SH.

Korean J Hepatol. 2011 Sep;17(3):199-205. doi: 10.3350/kjhep.2011.17.3.199.

9.

Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.

Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G.

Neth J Med. 2008 May;66(5):191-5.

10.

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH.

Dig Dis Sci. 2015 Feb;60(2):573-81. doi: 10.1007/s10620-014-3361-6. Epub 2014 Sep 19.

PMID:
25236421
11.
12.

Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.

Liu CJ.

J Gastroenterol Hepatol. 2014 Jan;29(1):26-30. doi: 10.1111/jgh.12421. Review.

PMID:
24199625
13.

Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.

Uyanikoglu A, Akyuz F, Baran B, Simsek BP, Ermis F, Demir K, Gulluoglu M, Badur S, Kaymakoglu S.

Clin Res Hepatol Gastroenterol. 2013 Nov;37(5):485-90. doi: 10.1016/j.clinre.2013.03.002. Epub 2013 May 9.

PMID:
23665172
14.

Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.

Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T.

J Viral Hepat. 2014 May;21(5):357-65. doi: 10.1111/jvh.12151. Epub 2013 Aug 25.

PMID:
24716638
15.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf.

PMID:
23395996
16.

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, Lin ZY, Hu TH, Chen CH, Hung CH, Wang JH, Chen CL, Kao JH, Lai MY, Liu CH, Su TH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Chen PJ, Liu CJ, Chen DS.

J Infect Dis. 2010 Jul 1;202(1):86-92. doi: 10.1086/653209.

PMID:
20482252
17.

Treatment of hepatitis B and C in children.

El-Shabrawi M, Hassanin F.

Minerva Pediatr. 2014 Oct;66(5):473-89. Review.

PMID:
25253190
18.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
19.

Long-term effects of interferon-based therapy for chronic hepatitis C.

Yu ML, Huang CF, Dai CY, Huang JF, Chuang WL.

Oncology. 2007;72 Suppl 1:16-23. Epub 2007 Dec 13. Review.

PMID:
18087178
20.

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.

Int J Cancer. 2000 Sep 1;87(5):741-9.

Supplemental Content

Support Center